Divi's Laboratories Limited (IN:DIVISLAB)
:DIVISLAB
DIVISLAB Stock Chart & Stats
₹6603.05
-₹20.75(-0.35%)
At close: 4:00 PM EST
₹6603.05
-₹20.75(-0.35%)
Day’s Range― - ―
52-Week Range₹4,941.70 - ₹7,077.70
Previous CloseN/A
Volume63.15K
Average Volume (3M)6.36K
Market Cap
₹1.59T
Enterprise Value₹1.57T
Total Cash (Recent Filing)₹32.61B
Total Debt (Recent Filing)₹900.00M
Price to Earnings (P/E)72.7
Beta0.87
Next Earnings
May 25, 2026EPS Estimate
25.33Next Dividend Ex-DateN/A
Dividend Yield0.46%
Share Statistics
EPS (TTM)21.98
Shares Outstanding265,468,570
10 Day Avg. Volume6,055
30 Day Avg. Volume6,356
Financial Highlights & Ratios
PEG Ratio1.82
Price to Book (P/B)9.84
Price to Sales (P/S)15.74
P/FCF Ratio290.01
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)97.57
Revenue Forecast (FY)₹106.13B
Bulls Say, Bears Say
Bulls Say
Strong Balance Sheet & Low LeverageVery low leverage and a high equity ratio provide durable financial flexibility. This supports funding capacity expansion, regulatory compliance investments and buffers cyclical API demand, reducing refinancing risk and enabling strategic M&A or capex without stressing liquidity over the medium term.
Robust Profitability And Net MarginsSustained high net margins demonstrate structural operating efficiency and pricing power in core businesses. Healthy operating profitability supports reinvestment in process R&D and capacity, providing a margin cushion versus commoditization risks and improving long-term cash generation potential.
Scale And Custom Synthesis (CRAMS) CapabilitiesLarge-scale manufacturing and process chemistry expertise underpin cost-competitive API production and CDMO offerings. Scale and technical capabilities drive long-term customer stickiness, multi-year contracts and higher-value custom work, supporting diversified revenue streams and resilience to single-product shocks.
Bears Say
Free Cash Flow VolatilityVolatile free cash flow reduces predictability of internal funding for capex, working capital and shareholder returns. This can constrain investment pacing, force episodic external financing, and raise execution risk for multi-year capacity projects or custom-synthesis investments over the medium term.
Gross Margin CompressionA meaningful decline in gross margin signals structural shifts in product mix or rising input costs. Persistently lower gross margins erode the buffer available for SG&A and R&D, making earnings more sensitive to pricing pressure in commoditized API markets and reducing long-run profitability resilience.
Exposure To Generic API Pricing & Product-mix RiskRevenue and margin durability hinge on winning higher-value custom contracts and favorable pricing in generics. Structural exposure to commoditized APIs and shifting customer demand can depress volumes and prices, making sustained revenue growth and margin recovery contingent on successful pipeline of higher-value work.
Divi's Laboratories Limited News
DIVISLAB FAQ
What was Divi's Laboratories Limited’s price range in the past 12 months?
Divi's Laboratories Limited lowest stock price was ₹4941.70 and its highest was ₹7077.70 in the past 12 months.
What is Divi's Laboratories Limited’s market cap?
Divi's Laboratories Limited’s market cap is ₹1.59T.
When is Divi's Laboratories Limited’s upcoming earnings report date?
Divi's Laboratories Limited’s upcoming earnings report date is May 25, 2026 which is in 56 days.
How were Divi's Laboratories Limited’s earnings last quarter?
Divi's Laboratories Limited released its earnings results on Feb 11, 2026. The company reported ₹21.98 earnings per share for the quarter, missing the consensus estimate of ₹23.173 by -₹1.193.
Is Divi's Laboratories Limited overvalued?
According to Wall Street analysts Divi's Laboratories Limited’s price is currently Overvalued.
Does Divi's Laboratories Limited pay dividends?
Divi's Laboratories Limited pays a Annually dividend of ₹30 which represents an annual dividend yield of 0.46%. See more information on Divi's Laboratories Limited dividends here
What is Divi's Laboratories Limited’s EPS estimate?
Divi's Laboratories Limited’s EPS estimate is 25.33.
How many shares outstanding does Divi's Laboratories Limited have?
Divi's Laboratories Limited has 265,468,570 shares outstanding.
What happened to Divi's Laboratories Limited’s price movement after its last earnings report?
Divi's Laboratories Limited reported an EPS of ₹21.98 in its last earnings report, missing expectations of ₹23.173. Following the earnings report the stock price went up 4.889%.
Which hedge fund is a major shareholder of Divi's Laboratories Limited?
Currently, no hedge funds are holding shares in IN:DIVISLAB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Divi's Laboratories Limited
Divi's Laboratories Limited manufactures and sells generic active pharmaceutical ingredients (APIs) and intermediates, and nutraceutical ingredients in India, the United States, Asia, Europe, and internationally. It also undertakes custom synthesis of APIs and intermediates; and supplies a range of carotenoids, as well as markets vitamins to nutritional, pharma, food/beverage, and feed industries. The company was formerly known as Divi's Research Center and changed its name to Divi's Laboratories Limited in 1994. The company was incorporated in 1990 and is headquartered in Hyderabad, India.
Technical Analysis
Dr. Reddy's Laboratories Ltd.
―
Laurus Labs Ltd.
―
Lupin Limited
―
Suven Life Sciences Limited
―
Torrent Pharmaceuticals Ltd
―